[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 131, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Office", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Mr. Harry R. Trout III", "age": 55, "title": "Interim Principal Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.66, "open": 8.57, "dayLow": 8.25, "dayHigh": 8.855, "regularMarketPreviousClose": 8.66, "regularMarketOpen": 8.57, "regularMarketDayLow": 8.25, "regularMarketDayHigh": 8.855, "payoutRatio": 0.0, "beta": 0.845, "forwardPE": -1.7178422, "volume": 221016, "regularMarketVolume": 221016, "averageVolume": 163227, "averageVolume10days": 175960, "averageDailyVolume10Day": 175960, "bid": 6.3, "ask": 10.66, "bidSize": 2, "askSize": 2, "marketCap": 177009008, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 13.37, "priceToSalesTrailing12Months": 2.7313676, "fiftyDayAverage": 7.8474, "twoHundredDayAverage": 6.7061, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 179996208, "profitMargins": -1.41981, "floatShares": 14330477, "sharesOutstanding": 21377900, "sharesShort": 2833975, "sharesShortPriorMonth": 2731581, "sharesShortPreviousMonthDate": 1753920000, "dateShortInterest": 1756425600, "sharesPercentSharesOut": 0.13260001, "heldPercentInsiders": 0.06632, "heldPercentInstitutions": 0.86526, "shortRatio": 18.69, "shortPercentOfFloat": 0.1408, "impliedSharesOutstanding": 21377900, "bookValue": 3.708, "priceToBook": 2.2330096, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -92012000, "trailingEps": -4.32, "forwardEps": -4.82, "enterpriseToRevenue": 2.777, "enterpriseToEbitda": -1.935, "52WeekChange": -0.29889923, "SandP52WeekChange": 0.16885936, "quoteType": "EQUITY", "currentPrice": 8.28, "targetHighPrice": 25.0, "targetLowPrice": 7.0, "targetMeanPrice": 17.42857, "targetMedianPrice": 20.0, "recommendationMean": 1.85714, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 204111008, "totalCashPerShare": 9.548, "ebitda": -93036000, "totalDebt": 207098000, "quickRatio": 4.769, "currentRatio": 4.999, "totalRevenue": 64806000, "debtToEquity": 261.227, "revenuePerShare": 3.044, "returnOnAssets": -0.17292, "returnOnEquity": -0.80644, "grossProfits": 64806000, "freeCashflow": -30994500, "operatingCashflow": -23183000, "revenueGrowth": 0.019, "grossMargins": 1.0, "ebitdaMargins": -1.43561, "operatingMargins": -1.03162, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "fiftyTwoWeekLowChange": 4.1899996, "fiftyTwoWeekLowChangePercent": 1.0244497, "fiftyTwoWeekRange": "4.09 - 13.37", "fiftyTwoWeekHighChange": -5.09, "fiftyTwoWeekHighChangePercent": -0.3807031, "fiftyTwoWeekChangePercent": -29.889923, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.32, "epsForward": -4.82, "epsCurrentYear": -3.71667, "priceEpsCurrentYear": -2.2278006, "corporateActions": [], "postMarketTime": 1757710651, "regularMarketTime": 1757707201, "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "marketState": "CLOSED", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -4.38799, "regularMarketPrice": 8.28, "fiftyDayAverageChange": 0.43259954, "fiftyDayAverageChangePercent": 0.05512648, "twoHundredDayAverageChange": 1.5738997, "twoHundredDayAverageChangePercent": 0.23469673, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": 0.0, "postMarketPrice": 8.28, "postMarketChange": 0.0, "regularMarketChange": -0.38, "regularMarketDayRange": "8.25 - 8.855", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 163227, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-09-13"}]